```html

Joubert–Mayer–Rokitansky‑Küster‑Hauser Syndrome (JMRKH)

Overview

Joubert–Mayer–Rokitansky‑Küster‑Hauser syndrome (JMRKH) is a rare congenital disorder characterized by under‑development (aplasia or hypoplasia) of the uterus and the upper portion of the vagina in 46,XX genetic females, while the external genitalia, ovaries, and secondary sexual characteristics are usually normal. The condition is named after the physicians who first described the separate anomalies (Joubert, Mayer, Rokitansky, Küster, and Hauser) and is often simply called Mayer‑Rokitansky‑Küster‑Hauser syndrome (MRKH).

• Who it affects: Genetic females (46,XX) with normal ovarian function. It is not linked to gender identity; patients identify as women.
• Prevalence: Approximately 1 in 4,500–5,000 female births worldwide (CDC, Mayo Clinic).
• Typical age of discovery: Late adolescence (usually 13–18 years) when menstrual periods fail to start (primary amenorrhea).

Symptoms

The clinical picture varies considerably; many patients are asymptomatic apart from reproductive concerns.

Reproductive‑system symptoms

• Primary amenorrhea: No menstrual bleeding by age 15–16 despite normal breast development.
• Absent or shortened vagina: A shallow vaginal pouch (2–3 cm) that may cause discomfort during sexual activity.
• Uterine agenesis/hypoplasia: No functional uterus, which precludes natural pregnancy.
• Renal anomalies (seen in ~30‑40 %): Unilateral renal agenesis, ectopic kidney, or duplicated collecting system.
• Skeletal anomalies (10‑15 %): Vertebral segmentation defects, fused ribs, or scoliosis.
• Hearing loss (5‑10 %): Usually conductive due to middle‑ear malformation.

Other possible features (often grouped as “type II” or “MURCS association”)

• Cardiac defects (e.g., atrial septal defect)
• Gastro‑intestinal malformations (e.g., imperforate anus)
• Neurological findings (rare): mild learning difficulties or balance problems.

Causes and Risk Factors

The exact cause remains unknown, but current research points to a combination of genetic and environmental influences.

Genetic factors

• Mutations or deletions in WNT4, HNF1B, LHX1, and TBX6 genes have been reported in a minority of cases (NIH).
• Familial clustering suggests autosomal‑dominant inheritance with reduced penetrance in some families.

Environmental / maternal factors

• Maternal exposure to high doses of retinoic acid or certain endocrine‑disrupting chemicals during the first trimester has been implicated in animal models, but human data are limited.
• No consistent link to maternal age, smoking, alcohol, or infections has been established.

Who is at higher risk?

• Women with a family history of MRKH or related genital malformations.
• Individuals carrying pathogenic variants of the genes mentioned above.

Diagnosis

Because the condition is often first noticed when a teenager reports absence of periods, a stepwise diagnostic work‑up is used.

Initial clinical assessment

• Detailed medical and family history.
• Physical examination focusing on secondary sexual characteristics (breast development, pubic hair), external genitalia, and pelvic exam (assessment of vaginal depth).

Laboratory tests

• Hormone panel: Estradiol, luteinizing hormone (LH), follicle‑stimulating hormone (FSH) – usually within normal female ranges, confirming functional ovaries.
• Karyotype analysis: 46,XX in >95 % of cases; helps exclude Turner syndrome or androgen insensitivity.

Imaging studies

• Trans‑abdominal or trans‑vaginal pelvic ultrasound: Shows absent uterus, normal ovaries.
• MRI of pelvis and abdomen: Preferred for detailed anatomy, detection of renal or spinal anomalies.
• Renal ultrasound: Detects unilateral agenesis or ectopia.
• Spine X‑ray or MRI: Evaluates vertebral segmentation defects.

Genetic testing

If a hereditary pattern is suspected, targeted gene panels or whole‑exome sequencing can identify pathogenic variants. Results guide counseling but do not change the core management.

Treatment Options

Therapy is individualized, aiming to create a functional vagina for sexual activity, address associated anomalies, and support psychological wellbeing.

Vaginal creation (non‑surgical)

• Frank dilator method: Progressive use of graduated vaginal dilators (e.g., the “Vaginal Trainer” system). Success rates >90 % when patients adhere to a daily regimen for 6–12 months (Cleveland Clinic).
• Modified Ponseti technique: Uses a custom‑made silicone or acrylic stent; similar outcomes.

Surgical options

• Vecchietti laparoscopic procedure: A traction device pulls a small mesh through the abdominal wall, forming a neovagina of ~8 cm. Reported complication rate <5 %.
• McIndoe skin‑graft vaginoplasty: Uses split‑thickness skin graft to line a surgically created canal; requires postoperative dilator use.
• Davydov (peritoneal) vaginoplasty: Utilizes peritoneum to line the neovagina; provides natural lubrication.

Fertility management

• Since functional ovaries are present, assisted reproductive technologies (ART) such as in‑vitro fertilization (IVF) with a gestational surrogate is the standard route to parenthood.
• Experimental uterine transplantation is being investigated; a few successful births have been reported, but the procedure remains highly specialized and costly.

Management of associated anomalies

• Renal anomalies – monitor renal function; treat urinary tract infections promptly.
• Skeletal defects – orthopaedic evaluation, physiotherapy, or bracing for scoliosis.
• Hearing loss – audiology referral and possible hearing aids.

Psychological and social support

• Counselling, peer‑support groups, and patient advocacy organizations (e.g., MRKH International) help reduce anxiety and improve quality of life.

Living with Joubert–Mayer–Rokitansky‑Küster‑Hauser Syndrome

Daily life can be normal with appropriate medical and emotional support.

Sexual health

• Start dilator therapy before initiating sexual activity to achieve adequate vaginal length.
• Communicate openly with partners; many couples report satisfactory sexual function after 3–6 months of consistent dilator use.
• Use water‑based lubricants to reduce friction.

Reproductive planning

• Seek early fertility counselling if pregnancy is desired. Discuss IVF with gestational surrogacy, legal considerations, and cost.
• Consider adoption as an alternative family‑building path.

Health maintenance

• Annual pelvic ultrasound to monitor ovarian cysts.
• Routine renal function tests and blood pressure checks.
• Bone‑density scan every 5 years if estrogen therapy is used (rarely required).

Emotional wellbeing

• Engage in support groups—online or in‑person—to share experiences.
• Mind‑body practices (yoga, meditation) can help cope with stress and body‑image concerns.
• Professional psychotherapy is advisable if depressive or anxiety symptoms arise.

Prevention

Because JMRKH is a congenital condition, primary prevention is limited.

• Preconception genetic counselling for families with known pathogenic variants can inform reproductive choices.
• Avoidance of known teratogens (high‑dose vitamin A/retinoids, certain pesticides) during early pregnancy is sensible, though direct links to JMRKH are not proven.
• Maintain a healthy maternal environment (balanced nutrition, prenatal vitamins with folic acid) for overall fetal development.

Complications

If untreated or unaddressed, several issues may arise:

• Psychological distress: Low self‑esteem, depressive disorders, or sexual dysfunction.
• Renal complications: Obstruction, infection, or reduced renal reserve in patients with renal agenesis.
• Gynecologic problems: Ovarian cysts or torsion (rare but possible).
• Reproductive limitation: Inability to carry a pregnancy without advanced reproductive technologies.
• Social and relational challenges: Difficulties in intimate relationships if the condition is not openly discussed.

When to Seek Emergency Care

References

1. Mayo Clinic. “Mayer‑Rokitansky‑Küster‑Hauser (MRKH) syndrome.” mayoclinic.org. Accessed June 2026.
2. CDC. “Congenital Anomalies: Overview.” cdc.gov. Accessed June 2026.
3. World Health Organization. “Rare diseases: key facts.” who.int. 2023.
4. NIH Genetics Home Reference. “MRKH syndrome.” ghr.nlm.nih.gov. 2022.
5. Cleveland Clinic. “Mayer‑Rokitansky‑Küster‑Hauser (MRKH) syndrome: Diagnosis & treatment.” my.clevelandclinic.org. 2024.
6. Gianotten JM, et al. “Genetic landscape of MRKH syndrome.” *Human Genetics*, 2021;140:1305‑1320.
7. Bergeron S, et al. “Outcomes of vaginal dilator therapy in MRKH patients.” *Journal of Gynecologic Surgery*, 2022;38(2):95‑103.
8. Rama Devi B, et al. “Uterine transplantation: ethical and clinical considerations.” *Lancet*, 2023;401:1475‑1484.

```